DocMorris AG
Double-digit growth for the Zur Rose Group in 2017
EQS Group-News: Zur Rose Group AG / Key word(s): Development of Sales Press release Double-digit growth for the Zur Rose Group in 2017 In financial year 2017 the Zur Rose Group successfully achieved its growth targets with a turnover just short of a billion. Sales increased organically by 11.8 percent to CHF 982.9 million (10.7 percent in local currency). In the fourth quarter they rose by 16.8 percent compared with the same period of the previous year, with growth continuing to accelerate compared with the third quarter. The turnover of the acquisitions Eurapon and Vitalsana, representing business of lasting relevance for the Group, would amount to EUR 85 million in 2017. Boost to market leadership in Germany. Significant sales growth in Switzerland The Zur Rose Group will publish its full annual report for 2017 on 21 March 2018.
Sales figures (unaudited)
1) consolidated as of 1 May 2017 Investor and analyst contact Media contact Zur Rose Group Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe’s largest mail-order pharmacy and one of Switzerland’s leading wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care. while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders. Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG’s shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.
End of Corporate News |
Language: | English |
Company: | Zur Rose Group AG |
Walzmühlestrasse 60 | |
8500 Frauenfeld | |
Switzerland | |
Phone: | +41 52 724 08 14 |
Internet: | www.zurrosegroup.com |
ISIN: | CH0199729366, CH0042615283 |
Listed: | SIX Swiss Exchange |
End of News | EQS Group News Service |